Vaccine Branch
Molecular Immunogenetics and Vaccine Research Section
Head, Clinical Trials Team Staff Clinician

National Cancer Institute
Building 10, Room 6B04
10 Center Drive, MSC 1578
Bethesda, MD 20892-1578

Phone: 301-402-0199
Fax: 301-480-8437
woodl@mail.nih.gov

Dr.Wood is a board certified allergist/immunologist and head of the Vaccine Branch Clinical Trials Team. She earned her B.A. in biology from Oberlin College and her M.D. from Duke University School of Medicine. She completed a combined residency in internal medicine and pediatrics at Baylor College of Medicine Affiliated Hospitals in Houston, TX, and is board certified in both specialties. Dr. Wood then completed a fellowship in allergy and immunology at NIAID and spent two years in the laboratory of Dr. Anthony Fauci investigating HIV-specific cellular and humoral immune responses. Following her fellowship, she worked for one year with Drs. Henry Masur and H. Clifford Lane in the NIAID HIV/AIDS Clinical Research Program before being recruited to NCI in 1992 by Dr. Philip Pizzo. As a member of the senior staff of the Pediatric HIV Working Group—initially under Dr. Pizzo and subsequently under Dr. Robert Yarchoan—her clinical research focused on the investigation of antiretroviral agents and immune-based therapies in HIV-infected children, adolescents, and young adults, including the initial studies of lamivudine (3TC) and ritonavir that led to FDA approval for their use in children. Dr. Wood also conducted studies of recombinant IL-2, HIV therapeutic vaccines, and adherence to antiretroviral treatment and investigated the infectious, malignant and psychosocial complications of pediatric HIV disease in collaboration with other NCI colleagues. In 2005, Dr. Wood joined the Vaccine Branch and was charged with developing a clinical translational research program, which she now heads.

Dr. Wood is an assistant professor at the Uniformed Services University of the Health Sciences and is a captain in the U.S. Public Health Service. She has served on multiple FDA, White House, and other interagency advisory, review, and data safety monitoring committees. Her work has been published, and she has been invited to present her work at national and international scientific meetings.

Dr. Wood's Clinical Trial(s):

NCI’s Center for Cancer Research (CCR) is currently conducting a clinical trial evaluating the safety and immune response to a therapeutic cancer vaccine designed to stimulate the immune system to recognize HER2/neu (HER2), in patients with solid tumors. Follow the links below to view a brief informational video by Dr. Wood about this trial:
Informational YouTube video for healthcare providers
Informational YouTube video for patients

Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.

A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/neu ECTM in Adults With Tumors With 1-3+ HER2/neu Expression NCI-13-C-0016, NCT01730118